Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells

Bone Marrow Transplantation

Volumn 33, Issue 1, 2004, Pages 53-60

  Rapoport, A P ^a   Levine, B L ^b   Badros, A ^a   Meisenberg, B ^a   Ruehle, K ^a   Nandi, A ^a   Rollins, S ^a   Natt, S ^a   Ratterree, B ^a   Westphal, S ^a   Mann, D ^a   June, C H ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Autotransplantation; Chronic myelogenous leukemia; CML; Costimulation; Imatinib mesylate; T cell immunotherapy

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; BCR ABL PROTEIN; CARMUSTINE; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DIPHENHYDRAMINE; EMOLLIENT AGENT; ETOPOSIDE; FAMCICLOVIR; FLUCONAZOLE; GEMCITABINE; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; LEVOFLOXACIN; MELPHALAN; MEPERIDOL; MESNA; MESSENGER RNA; PARACETAMOL; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CAPILLARY LEAK SYNDROME; CASE REPORT; CHILL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DERMATITIS; DRUG ERUPTION; DYSPNEA; FEASIBILITY STUDY; FEVER; FOLLOW UP; HEMATOLOGIC DISEASE; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; LUNG INFILTRATE; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MENTAL DISEASE; PERIPHERAL EDEMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STEM CELL MOBILIZATION; SURVIVAL TIME; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MIDDLE AGED; POLYMERASE CHAIN REACTION; REMISSION INDUCTION; RNA, NEOPLASM; SALVAGE THERAPY; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 10744233830     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704317     Document Type: Article

References (37)

1. Kantarjian HM, Deisseroth A, Kurzrock R et al. Chronic myelogenous leukemia: a concise update. Blood 1993; 82: 691-703.
2. Thomas ED, Clift RA, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155-163.
3. Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962-968.
4. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T cell depletion. Ann Intern Med 1988; 108: 806-814.
5. Porter DL, Roth MS, McGarigle C et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330: 100-106.
6. Mackinnon S, Barnett L, Heller G, O'Reilly RJ. Minimal residual disease is more common in patients who have mixed T cell chimerism after bone marrow transplantation for chronic myelogenous leukaemia. Blood 1994; 83: 3409-3416.
7. van Rhee F, Lin F, Cullis JO et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation: the case for giving donor leukocyte transfusions before the onset of hematological relapse. Blood 1994; 83: 3377-3383.
8. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
9. Marks DI, Cullis JO, Ward KN et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. Ann Intern Med 1993; 119: 207-214.
10. Hoyle C, Gray R, Goldman J. Autografting for patients with CML in chronic phase: an update. Br J Haematol 1994; 86: 76-81.
11. Khouri F, Kantarjian HM, Talpaz M et al. Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: The MD Anderson experience. Bone Marrow Transplant 1996; 17: 775-779.
12. Carella AM, Lerma E, Corsetti MT et al. Autografting with Philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 1999; 93: 1534-1539.
13. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
14. Falkenburg JHF, Smit WM, Willemze R. Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. Immunol Rev 1997; 157: 223-230.
15. Faber LM, van Luxemburg-Heijs SA, Rijnbeek M et al. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of α-interferon. Biol Blood Marrow Transplant 1996; 2: 31-36.
16. Molldrem JJ, Clave E, Jiang YZ et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997; 90: 2529-2534.
17. Bocchia M, Korontsvit T, Xu Q et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996; 87: 3587-3592.
18. Bhatia R, McGlave PB. T lymphocytes cultured from chronic myelogenous leukemia bone marrow suppress autologous hematopoietic progenitors. Leukemia 1995; 9: 1006-1012.
19. Coleman S, Fisher J, Hoy T et al. Autologous MHC-dependent leukaemia-reactive T lymphocytes in a patient with chronic myeloid leukaemia. Leukemia 1996; 10: 483-487.
20. Coleman S, Throp D, Fisher J et al. Cytokine enhancement of immunogenicity in chronic myeloid leukaemia. Leukemia 1997; 11: 2055-2059.
21. Choudhury A, Gajewski JL, Liang JC et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997; 89: 1133-1142.
22. Eibl B, Ebner S, Duba C et al. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T cell response. Genes Chromosomes Cancer 1997; 20: 215-223.
23. Papadopoulos KP, Suciu-Foca N, Hesdorffer CS et al. Naturally processed tissue- and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts. Blood 1997; 90: 4938-4946.
24. Brown RA, Herzig RH, Wolf SN et al. High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 1990; 76: 473-479.
25. Rapoport AP, Meisenberg B, Sarkodee-Adoo C et al. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant 2002; 29: 303-312.
26. Levine BL, Bernstein WB, Connors M et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feed cells. J Immunol 1997; 159: 5921-5930.
27. Levine BL, Cotte J, Small CC et al. Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother 1998; 7: 437-448.
28. Laport GG, Levine BL, Stadtmauer EA et al. Induction of lymphocytosis following adoptive transfer of costimulated T cells in patients with relapsed/refractory non-Hodgkin's lymphoma following CD34-selected hematopoietic cell transplantation. Blood 2003; 102: 2004-2013.
29. Bomberger C, Singh-Jairam M, Rodey G et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood 1998; 91: 2588-2600.
30. Divine M, Boutolleau D, Delfau-Larue MH et al. Poor lymphocyte recovery following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Br J Haematol 1999; 105: 349-360.
31. Porrata LF, Gertz MA, Inwards DJ et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579-585.
32. Porrata LF, Litzow MR, Terreri A et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 2002; 16: 1311-1318.
33. Porrata LF, Inwards DJ, Micallef IN et al. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol 2002; 117: 629-633.
34. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854.
35. Rowe JM, Rapoport AP, Ryan DH et al. Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex. Bone Marrow Transplant 1999; 24: 1057-1063.
36. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 14: 1031-1037.
37. Kantarjian HM, Cortes JE, O'Brien S et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic response. Blood 2003; 101: 97-100.